Cytogenetic evolution of human ovarian cell lines associated with chemoresistance and loss of tumorigenicity

被引:4
作者
Struski, S
Doco-Fenzy, M
Koehler, M
Chudoba, I
Levy, F
Masson, L
Michel, N
Ulrich, E
Gruson, N
Bénard, J
Potron, G
Cornillet-Lefebvre, P
机构
[1] Hop Robert Debre, Hematol Lab, F-51100 Reims, France
[2] Fac Med, UPRES EA 20 70, IFR Biomol 53, F-51100 Reims, France
[3] Maison Blanche Hosp, Lab Cytogenet, F-51100 Reims, France
[4] ASI GmbH, D-68309 Mannheim, Germany
[5] MetaSyst, D-68804 Altlussheim, Germany
[6] Polytec Pl, Electroopt Div, F-93694 Pantin, France
[7] Inst Gustave Roussy, F-94800 Villejuif, France
来源
ANALYTICAL CELLULAR PATHOLOGY | 2003年 / 25卷 / 03期
关键词
D O I
10.1155/2003/151042
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to identify genomic changes associated with a resistant phenotype acquisition, we used comparative genomic hybridization (CGH) to compare a human ovarian cell line, Igrov1, and four derived subcell lines, resistant to vincristine and presenting a reversion of malignant properties. Multicolor FISH (Multiplex-FISH and Spectral Karyotype) and conventional FISH are also used to elucidate the karyotype of parental cell line. The drug-resistant subcell lines displayed many chromosomal abnormalities suggesting the implication of different pathways leading to a multidrug resistance phenotype. However, these cell lines shared two common rearrangements: an unbalanced translocation der(8)t(8;13)(p22;q?) and a deletion of the 11p. These chromosomal imbalances could reflected the acquisition of the chemoresistance (der(8)) or the loss of tumorigenicity properties (del(11p)). Colour figure can be viewed on http://www.esacp.org/acp/2003/25-3/struski.htm.
引用
收藏
页码:115 / 122
页数:8
相关论文
共 36 条
[31]  
Struski S, 2001, GENE CHROMOSOME CANC, V30, P136, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1071>3.0.CO
[32]  
2-T
[33]   DRUG-RELATED CHROMOSOMAL CHANGES IN CHEMORESISTANT HUMAN OVARIAN-CARCINOMA CELLS [J].
TEYSSIER, JR ;
BENARD, J ;
FERRE, D ;
DASILVA, J ;
RENAUD, L .
CANCER GENETICS AND CYTOGENETICS, 1989, 39 (01) :35-43
[34]   A MULTIDRUG-RESISTANT OVARIAN-CARCINOMA CELL-LINE WITH A MALIGNANT SUPPRESSED PHENOTYPE IS A CD44 GENE-EXPRESSION DEFECTIVE MUTANT [J].
TEYSSIER, JR ;
COUILLIN, P ;
BENARD, J ;
RAVISSE, N ;
ULRICH, E ;
CORNILLET, P .
CANCER GENETICS AND CYTOGENETICS, 1992, 60 (01) :14-19
[35]  
Wasenius VM, 1997, GENE CHROMOSOME CANC, V18, P286, DOI 10.1002/(SICI)1098-2264(199704)18:4<286::AID-GCC6>3.3.CO
[36]  
2-A